These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10831925)

  • 1. Monitoring individual response to hormone replacement therapy with bone markers.
    Delmas PD; Hardy P; Garnero P; Dain M
    Bone; 2000 Jun; 26(6):553-60. PubMed ID: 10831925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
    Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
    Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
    Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover.
    Garnero P; Darte C; Delmas PD
    Bone; 1999 Jun; 24(6):603-9. PubMed ID: 10375203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women.
    Bjarnason NH; Christiansen C
    Bone; 2000 Jun; 26(6):561-9. PubMed ID: 10831926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
    Collette J; Viethel P; Dethor M; Chevallier T; Micheletti MC; Foidart JM; Reginster JY
    Gynecol Obstet Fertil; 2003 May; 31(5):434-41. PubMed ID: 14567121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women?
    Heikkinen AM; Kröger H; Niskanen L; Komulainen MH; Ryynänen M; Parviainen MT; Tuppurainen MT; Honkanen R; Saarikoski S
    Maturitas; 2000 Jan; 34(1):33-41. PubMed ID: 10687880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
    Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
    Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The decrease in serum bone-specific alkaline phosphatase predicts bone mineral density response to hormone replacement therapy in early postmenopausal women.
    Dresner-Pollak R; Mayer M; Hochner-Celiniker D
    Calcif Tissue Int; 2000 Feb; 66(2):104-7. PubMed ID: 10652956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P; Clemmesen B; Christiansen C
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.